Skip to content
Open access

Preclinical evaluation of ixazomib for high-risk pediatric brain tumors

Sep 2026 · bioRxiv · 0 citations
Medicine Biology

TL;DR

Using transcriptomic and proteomic approaches, ixazomib effectively triggers proteostatic stress responses and induces apoptosis across a histologic range of CNS malignancies and is effective against Myc-MB, ATRT and DMG tumors in vitro.

Abstract

Background Many of the highest risk pediatric brain cancers continue to experience poor clinical outcomes despite intensification of current multimodal therapy. Proteasome inhibition has shown preclinical promise across a range of cancer models including diffuse midline glioma (DMG), medulloblastoma, and atypical teratoid / rhabdoid tumors (ATRT), though clinically viable agents have been limited. Recent studies in adults with glioblastoma suggest that ixazomib, a second-generation proteasome inhibitor, might achieve therapeutic concentrations in the CNS, presenting the opportunity that a CNS penetrant proteasome inhibitor might be similarly leveraged for benefit in childhood brain cancers. Methods Ixazomib was tested against cell lines and orthotopic xenograft models of DMG, Myc-amplified medulloblastoma (Myc-MB), and ATRT. RNA sequencing and LC-MS based proteomics were utilized to define functional consequences of ixazomib treatment in these models. Proteasome activity readouts were used to assess ixazomib activity across brain regions and extracranial solid organs. Results Ixazomib demonstrates consistent cytotoxic effect across high-risk brain tumor models at low nanomolar concentrations. Ixazomib treatment activates proteostatic stress response and apoptosis. Treatment with ixazomib does not demonstrate survival benefit in orthotopic models, however, and pharmacodynamic testing suggests insufficient inhibition of proteasome activity within the CNS compared to extracranial tissues. Conclusions While many pediatric brain tumor models demonstrate susceptibility to proteasome inhibition, ixazomib may lack sufficient blood-brain barrier penetration to be a translationally viable means of exploiting this vulnerability. Key Points Ixazomib is effective against Myc-MB, ATRT and DMG tumors in vitro Ixazomib treatment does not prolong survival in orthotopic models Ixazomib may fail to achieve sufficient suppression of proteasome activity within the CNS Importance of Study Many high-risk subsets of pediatric brain tumors continue to experience unsatisfactory clinical outcomes under current treatment regimens. Previous research has shown many of these diseases to be responsive to proteasome inhibition, and recent phase 0 data in glioblastoma has suggested that the agent ixazomib may achieve meaningful concentrations in the CNS following systemic administration. In this study, we test ixazomib across a range of pediatric brain tumor models. Using transcriptomic and proteomic approaches, we find that ixazomib effectively triggers proteostatic stress responses and induces apoptosis across a histologic range of CNS malignancies. Orthotopic models fail to demonstrate a survival benefit from ixazomib treatment, however, and pharmacodynamic readouts suggest limited proteasome suppression within the CNS. These findings caution further translational efforts for this agent in children with primary brain tumors.

Read PDF

Similar papers

Open access Oct 2026

Cytotoxic activity of selinexor in BRAFV600E-driven pediatric low-grade glioma 3D cultures

Pediatric low-grade gliomas (pLGGs) are the most common primary brain tumors in children and frequently harbor activating RAS/MAPK pathway alterations, including BRAFV600E. Although MEK inhibitors (MEKi) show clinical activity, responses are often incomplete and tumors commonly regrow after treatment discontinuation, h...

Constantia Zeiser, M. Emperador, S. Herter et al. · 0 citations
Oct 2026

Biomarker-guided treatment strategies for patients with gliomas in clinical practice.

Targeted therapy has made important contributions to improving outcomes for patients with many solid tumors, but has had only limited activity so far in patients with gliomas, notably glioblastoma. Failure of targeted therapy in glioblastoma is likely due to redundance of oncogenic pathway activation and so far the ina...

É. Le Rhun, I. Mellinghoff, Tobias Weiss et al. · 0 citations
Review Sep 2026

Precision medicine for pediatric gliomas.

PURPOSE OF REVIEW The fifth edition of the WHO Classification of Tumors of the Central Nervous System marked a paradigm shift from predominantly histopathological classification toward integrated molecular-pathological definitions. This review summarizes the contemporary molecular landscape of pediatric gliomas, pivota...

Lorena V. Baroni, É. Bouffet · 0 citations
Open access Oct 2026

Paxalisib with Trastuzumab for HER2-Positive Metastatic Breast Cancer with Active Brain Metastases: A Phase II Trial with Integrated Plasma and CSF ctDNA Analyses

Abstract Purpose: Human epidermal growth factor receptor 2 (HER2)–positive breast cancer brain metastases (BCBM) frequently harbor PI3K/AKT/mTOR alterations. Preclinical HER2+ BCBM models demonstrated durable tumor regression with dual PI3K and mTOR inhibition. Our phase II trial evaluated paxalisib, a brain-penetrant...

E. Seguí, Jorge Gómez Tejeda Zañudo, N. Graham et al. · 0 citations
Review Open access Oct 2026

Personalized Therapeutic Strategies in Glioblastoma: Bridging Molecular Markers and In Vivo Observations for Targeted Treatment

This review looks at how important molecular drivers, like metabolic changes caused by IDH1/2 mutations, MGMT promoter methylation status, receptor tyrosine kinase signaling involving EGFR and EGFRvIII, and changes in epigenetics seen in H3 K27M, are creating new opportunities in immunotherapy, CAR-T cell therapy, prec...

Joaquin Fiallo Arroyo, Jose E. Leon-Rojas · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.